Belfast Health and Social Care Trust
caring supporting improving together

FOI/27624

11 August 2022

Treatment of Colorectal Cancer (CRC) and Immune Thrombocytopenia

I have a freedom of information request. Could you please answer the following questions?

1. **Within your health Trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?**

   Answer as available from RISOH (Regional Information system Oncology/Haematology) April – June 22:

• **Aflibercept**	<5
• **Bevacizumab**	<5
• **Capecitabine**	18
• **CAPIRI (Irinotecan/Capcetabine(>/=65)(XELIRI)(Pall CRC))**	<5
• **CAPOX (XELOX)**	<5
• **Cetuximab in combination with FOLFIRI**	18
• **Cetuximab in combination with FOLFOX**	<5
• **Cetuximab not in combination with FOLFIRI or FOLFOX**	<5
• **Irinotecan only**	<5
• **FOLFIRI**	9
• **FOLFOX**	22
• **Fluorouracil (5FU) only**	<5
• **Oxaliplatin only**	<5
• **Panitumumab in combination with FOLFIRI**	<5
• **Panitumumab in combination with FOLFOX**	<5
• **Panitumumab not in combination with FOLFIRI or FOLFOX**	<5
• **Pembrolizumab**	5
• **Nivolumab**	<5
• **Raltitrexed**	<5
• **Ramucirumab**	<5
• **Regorafenib**	<5
• **Sorafenib**	<5
• **Other SACT**:	
Encorafenib & Cetuximab (CRC)	<5
Irinotecan & Raltitrexed (TOMIRI)	<5
Longsurf	<5
Mitomycin C & Capecitabine	<5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

11 August 2022

2. **In the last 3 months, how many patients has your Trust treated (for any condition) with the following treatments:**

   - **Avatrombopag** <5
   - **Eltrombopag** 32
   - **Fostamatinib** <5
   - **Romiplostim** <5

   As per Question 1, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.

3. **In the last 3 months, how many patients has your Trust treated for Immune Thrombocytopenia (ICD10 code D69.3)?**

   From January to March 2022, 48 patients were admitted as a daycase or inpatient with a diagnosis of Immune thrombocytopenia.

4. **In the last 3 months, how many patients has your Trust treated for Immune Thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:**

   - Avatrombopag
   - Mycophenolate mofetil
   - Rituximab
   - Surgery (splenectomy)

   This information is not held centrally. The Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.